

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS 4 FEB 28 PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS 5 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 6 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 7 MAR 02 GBFULL: New full-text patent database on STN
NEWS 8 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22 KOREPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22 PATDPASPC - New patent database available
NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 14 APR 04 EPFULL enhanced with additional patent information and new fields
NEWS 15 APR 04 EMBASE - Database reloaded and enhanced
NEWS 16 APR 18 New CAS Information Use Policies available online

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:25:08 ON 22 APR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY 0.21 SESSION 0.21

FILE 'REGISTRY' ENTERED AT 15:25:17 ON 22 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7
 DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10638848.str



chain nodes :

11 12 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18

chain bonds :

5-21 8-12 9-11 12-13

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 13-14 13-18 14-15 15-16
 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 3-4 3-10 4-5 5-6 5-21 8-12 9-10 9-11

exact bonds :

2-7 7-8 8-9 12-13

10/ 638,848

normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sample

SAMPLE SEARCH INITIATED 15:25:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 245 TO ITERATE

100.0% PROCESSED 245 ITERATIONS
SEARCH TIME: 00.00.01

40 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3961 TO 5839
PROJECTED ANSWERS: 421 TO 1179

L2 40 SEA SSS SAM L1

=> s 11 ful
FULL SEARCH INITIATED 15:26:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5837 TO ITERATE

100.0% PROCESSED 5837 ITERATIONS
SEARCH TIME: 00.00.01

955 ANSWERS

L3 955 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 161.33 | 161.54 |

FILE 'CAPLUS' ENTERED AT 15:26:07 ON 22 APR 2005

10/ 638,848

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005 VOL 142 ISS 18
FILE LAST UPDATED: 21 Apr 2005 (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> s 13
L4 16 L3

=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 16 ANSWERS - CONTINUE? Y/ (N) :y

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005-120672 CAPLUS
 DOCUMENT NUMBER: 142198094
 TITLE: Preparation of pyrimidopyrimidines as protein kinase inhibitors
 INVENTOR(S): Sim, Taebor; Lee, Hyun Soo; Ren, Pingda; Ding, Qiang;
 Wang, Xia; Uno, Tetsuo; Zhang, Guobao; Liu, Yi; Li,
 Bing; Li, Lintong; Gray, Nathaniel; You, Shuli
 PATENT ASSIGNEE(S): IBM LLC, Bermuda
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|-----------------|----------|-----------------|----------|
| WO 2005011597 | A2 | 20050210 | WO 2004-US24764 | 20040729 |
| WO 2005011597 | A3 | 20050324 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SK,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: | US 2003-491133P | P | 20030729 | GI |

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The invention provides a novel class of compds. I [n = 0-4; Z = N, CH; R1 = H, alkyl, acylalkyl, hydroxy, alkoxy, etc.; R2 = H, alkyl; or R1 and R2 together form O or S; R4 = H, OH, NH2, alkyl, etc.; R5 = alkyl, alkenyl, alkoxy, etc.; R6 = NR1Y(O)R13, Y(O)NR12R13 (wherein Y = C, P(O), S(O); R12 = H, alkyl; R13 = aryl, heteroaryl, cycloalkyl, etc.); pharmaceutical compds. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with abnormal

or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt1, Ikk, IR, JNK, Lck, Mnk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, Igf, Mek, Ros and Tie2 kinases. E.g., a multi-step synthesis of II, starting from 4-amino-2-methylsulfanylpurimidine-5-carbonitrile, was given. The compds. show a percentage inhibition of greater than 50% against the mentioned above kinases at 10 μ M.

IT 839705-51-OP 839705-52-12 839705-53-29
 839705-54-3P 839705-55-4P 839705-56-5P
 839705-57-6P 839705-58-7P 839705-59-6P
 839705-60-1P 839705-61-2P 839705-62-3P
 839705-63-4P 839705-64-5P 839705-65-6P
 839705-66-7P 839705-67-8P 839705-69-0P
 839705-70-3P 839705-71-4P 839705-72-5P
 839705-73-6P 839705-74-7P 839705-75-8P
 839705-76-9P 839705-77-0P 839705-78-1P
 839705-79-2P 839705-80-5P 839705-81-6P
 839705-82-7P 839705-83-8P 839705-84-9P
 839705-85-0P 839705-86-1P 839705-87-2P
 839705-88-3P 839705-89-4P 839705-90-7P

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

| | | | | |
|--------------|--------------|--------------|--|--|
| 839705-91-8P | 839705-92-9P | 839705-93-0P | | |
| 839705-94-1P | 839705-95-2P | 839705-96-3P | | |
| 839705-97-4P | 839705-98-5P | 839705-99-6P | | |
| 839706-00-2P | 839706-01-3P | 839706-02-4P | | |
| 839706-03-8P | 839706-04-6P | 839706-05-7P | | |
| 839706-06-8P | 839706-07-9P | 839706-08-0P | | |
| 839706-09-1P | 839706-10-4P | 839706-11-5P | | |
| 839706-12-6P | 839706-13-7P | 839706-14-8P | | |
| 839706-15-9P | 839706-16-0P | 839706-17-1P | | |
| 839706-18-2P | 839706-19-3P | 839706-20-6P | | |
| 839706-21-7P | 839706-22-8P | 839706-23-9P | | |
| 839706-24-0P | 839706-25-1P | 839706-26-2P | | |
| 839706-27-3P | 839706-28-4P | 839706-29-5P | | |
| 839706-30-8P | 839706-31-9P | 839706-32-0P | | |
| 839706-33-1P | 839706-34-2P | 839706-35-3P | | |
| 839706-36-4P | 839706-37-5P | 839706-38-6P | | |
| 839706-39-7P | 839706-40-0P | 839706-41-1P | | |
| 839706-42-2P | 839706-43-3P | 839706-44-4P | | |
| 839706-45-5P | 839706-46-6P | 839706-47-7P | | |
| 839706-48-6P | 839706-49-9P | 839706-50-2P | | |
| 839706-51-3P | 839706-52-4P | 839706-53-5P | | |
| 839706-54-6P | 839706-55-7P | 839706-56-8P | | |
| 839706-57-9P | 839706-58-0P | 839706-59-1P | | |
| 839706-60-4P | 839706-61-5P | 839706-62-6P | | |
| 839706-63-7P | 839706-64-8P | 839706-65-9P | | |
| 839706-66-0P | 839706-67-1P | 839706-68-2P | | |
| 839706-69-3P | 839706-70-6P | 839706-71-7P | | |
| 839706-72-0P | 839706-73-9P | 839706-74-0P | | |
| 839706-75-1P | 839706-76-2P | 839706-77-3P | | |
| 839706-78-4P | 839706-79-5P | 839706-80-6P | | |
| 839706-81-9P | 839706-82-0P | 839706-83-1P | | |
| 839706-84-2P | 839706-85-3P | 839706-86-4P | | |
| 839706-87-5P | 839706-88-6P | 839706-89-7P | | |
| 839706-90-0P | 839706-91-1P | 839706-93-3P | | |
| 839706-94-4P | 839706-96-6P | 839706-97-7P | | |
| 839706-98-0P | 839706-99-9P | 839707-00-5P | | |
| 839707-01-6P | 839707-02-7P | 839707-03-8P | | |
| 839707-04-9P | 839707-05-0P | 839707-06-1P | | |
| 839707-07-2P | 839707-08-3P | 839707-09-4P | | |
| 839707-10-7P | 839707-11-8P | 839707-12-9P | | |
| 839707-13-0P | 839707-14-1P | 839707-15-2P | | |
| 839707-16-3P | 839707-17-4P | 839707-18-5P | | |
| 839707-19-6P | 839707-20-9P | 839707-21-0P | | |
| 839707-22-1P | 839707-23-2P | 839707-24-3P | | |
| 839707-25-4P | 839707-26-5P | 839707-27-6P | | |
| 839707-28-7P | 839707-29-8P | 839707-30-1P | | |
| 839707-31-2P | 839707-32-3P | 839707-33-4P | | |
| 839707-34-5P | 839707-35-6P | 839707-36-7P | | |
| 839707-37-6P | 839707-38-9P | 839707-39-0P | | |
| 839707-40-3P | 839707-41-4P | 839707-43-6P | | |
| 839707-44-7P | 839707-45-9P | 839707-46-9P | | |
| 839707-47-0P | 839707-48-1P | 839707-49-2P | | |
| 839707-50-5P | 839707-51-6P | 839707-52-7P | | |
| 839707-53-8P | 839707-54-9P | 839707-55-0P | | |
| 839707-56-1P | 839707-57-2P | 839707-58-3P | | |
| 839707-59-4P | 839707-60-5P | 839707-61-6P | | |
| 839707-62-9P | 839707-63-0P | 839707-64-1P | | |
| 839707-65-2P | 839707-66-3P | 839707-67-4P | | |
| 839707-68-5P | 839707-69-6P | 839707-70-9P | | |
| 839707-71-0P | 839707-72-1P | 839707-73-2P | | |

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


839707-74-3P 839707-75-4P 839707-76-5P
 839707-77-6P 839707-78-7P 839707-79-8P
 839707-80-1P 839707-81-2P 839707-82-3P
 839707-83-4P 839707-84-5P 839707-85-6P
 839707-86-7P 839707-87-8P 839707-95-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


RN (propn. of pyrimidopyrimidines as protein kinase inhibitors)

CN 839705-51-0 CAPLUS


Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxo-7-(trifluoromethyl)-4-methylphenyl)-amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]- (9CI) (CA INDEX NAME)



CN 839705-52-1 CAPLUS
 Benzamide, N-[3-[(7-[[3-((aminocarbonyl)amino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




CN 839705-53-2 CAPLUS
 Benzamide, N-[3-[(1,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



CN 839705-54-3 CAPLUS
 Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

 $\rightarrow \text{CF}_3$

RN 839705-55-4 CAPLUS
CN Benzamide, N-[3-[7-[(3-(aminosulfonyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-56-5 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[(3-(2-hydroxyethyl)phenyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-57-6 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Benzamide, N-[3-[1-methyl-7-[(3-(4-methyl-1-piperazinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-58-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-phenoxydrazino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-59-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[(3-[(hydroxymethyl)amino]phenyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-60-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4H-1,2,4-triazol-4-ylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[(cyclopropylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-61-2 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-1-piperazinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 839705-62-3 CAPLUS
CN Benzamide, N-[3-[7-[(3-(formylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-63-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-64-5 CAPLUS



RN 839705-66-7 CAPLUS


CN Benzamide, N-[3-[(3-[(dimethylamino)phenyl]amino)-1,4-dihydro-1-(2-hydroxyethyl)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-67-8 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-[2-((1-methylethyl)amino)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PAGE 1-A




PAGE 1-B

 $\rightarrow \text{CF}_3$

RN 839705-69-0 CAPLUS
CN Benzonic acid, 3-[(5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[(3-trifluoromethyl)benzyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 839705-70-3 CAPLUS
CN Benzamide, N-[3-(7-(cyclobutylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-71-4 CAPLUS
CN Benzamide, N-[3-(7-(cyclopentylamino)-1,4-dihydro-1-methyl-2-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-72-5 CAPLUS
CN Benzamide, N-[3-[(1S)-1,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839705-73-6 CAPLUS
CN Benzamide, N-[3-[(1R)-1,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839705-74-7 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxo-7-(2-propenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839705-75-8 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(2-methyl-2-propenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-76-9 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxo-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-77-0 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(3-[(4-methyl-1-piperazinyl)methyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




PAGE 1-B

 $\rightarrow \text{NMe}_2$

RN 839705-78-1 CAPLUS
CN Benzamide, N-[3-[(7-[(3-[(dimethylamino)methyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-79-2 CAPLUS
CN Benzamide, N-[3-[(7-[(2-(dimethylamino)ethyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-80-5 CAPLUS
CN Benzamide, N-[3-[(7-[(2-aminoethyl)amino]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


→ CF3

RN 839705-81-6 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(3-[2-(methylamino)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-82-7 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(3-[2-(4-morpholinyl)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

→ CF3


RN 839705-83-8 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(4-[2-(4-morpholinyl)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



PAGE 1-B


→ CF3

RN 839705-84-9 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(3-[2-(methylamino)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-85-0 CAPLUS
 CN Benzamide, N-[3-[(4-(2-aminoethyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839705-86-1 CAPLUS
 CN Benzamide, N-[3-[(3-(2-aminoethyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-87-2 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(3-(4-morpholinyl)methyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-88-3 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-7-[(3-(1H-imidazol-1-yl)propyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-89-4 CAPLUS

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-2-oxo-7-[(3-[2-(1-piperazinyl)ethyl]phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

→ CF3

RN 839705-90-7 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-2-oxo-7-[(4-[2-(1-piperazinyl)ethyl]phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B

→ CF3


RN 839705-91-8 CAPLUS
 CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-[(3-methyl-5-isoxazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-92-9 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-(1-piperazinylmethyl)phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-93-0 CAPLUS
 CN Benzamide, N-[3-[7-[(4-(4-ethyl-1-piperazinyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-94-1 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(4-(1-piperazinyl)phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-95-2 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-((6-methyl-3-pyridinyl)amino)-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-96-3 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-97-4 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2,4-dioxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-98-5 CAPLUS
 CN Benzamide, N-[3-[7-((6-ethyl-3-pyridinyl)amino)-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-99-6 CAPLUS
 CN Benzamide, N-[3-[7-((6-ethenyl-3-pyridinyl)amino)-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-00-2 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(6-(trifluoromethyl)-3-pyridinyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-01-3 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-((6-[2-(4-morpholinyl)ethyl]amino)-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A


PAGE 1-B

—CF₃


RN 839706-02-4 CAPLUS
 CN Benzamide, N-[3-[7-((6-[2-(diethylamino)ethyl]amino)-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-03-5 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-((6-methyl-3-pyridinyl)amino)-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-04-6 CAPLUS
CN Benzamide, N-[3-[7-[(4-fluorophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-05-7 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-06-8 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-10-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-N-methyl-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-12-6 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-7-[(4-fluorophenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-07-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-09-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 839706-09-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-piperidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-13-7 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethenylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-14-1 CAPLUS
CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(3-methyl-5-isoxazolyl)amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-15-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 839706-16-0 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(4-[2-(4-morpholinyl)ethyl]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 839706-17-1 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-18-2 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-19-3 CAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-20-6 CAPLUS


CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-21-7 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(4-trifluoromethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-22-8 CAPLUS

CN Benzamide, N-[3-[1-phenylamino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-23-9 CAPLUS

CN Benzamide, N-[3-[(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-24-0 CAPLUS


CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-25-1 CAPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-26-2 CAPLUS

CN Benzamide, N-[3-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-27-3 CAPLUS


CN Benzamide, N-[3-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-28-4 CAPLUS

CN Benzamide, N-[3-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)







RN 839706-29-5 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-30-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-{{3-(2-oxo-1-pyrrolidinyl)propyl}amino}pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-31-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-32-0 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-33-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-34-2 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-35-3 CAPLUS
CN Benzamide, N-[3-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-36-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-37-5 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-38-6 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-39-7 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-40-0 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-41-1 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-42-2 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-43-3 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-44-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-45-5 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[{4-ethyl-1-piperazinyl}methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-46-6 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-47-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1,2-dihydro-2-oxo-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-48-8 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[{(4-ethyl-1-piperazinyl)methyl}- (9CI) (CA INDEX NAME)




RN 839706-49-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-1-[2-(4-morpholinyl)ethyl]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-50-2 CAPLUS
CN Benzamide, N-[3-{7-(ethylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl}-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-51-3 CAPLUS
CN Benzamide, N-[3-{7-(cyclopropylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxypyrimido[4,5-d]pyrimidin-3(2H)-yl}-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 839706-52-4 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-2-propenyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-53-5 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-54-6 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-[(4-(4-morpholinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-55-7 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-56-8 CAPLUS
 CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-57-9 CAPLUS
 CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-58-0 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-59-1 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-60-4 CAPLUS
 CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-61-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 839706-62-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-63-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)



RN 839706-64-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-65-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-ethyl-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-66-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N,N-dimethyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-67-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-cyclopropyl-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-68-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-hydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-69-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-(ethylamino)-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-70-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-71-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[(4,6-dimethyl-3-pyridinyl)amino]-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-72-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-73-9 CAPLUS
 CN Benzamide, N-3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-74-0 CAPLUS
 CN Benzamide, N-3-[(7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-75-1 CAPLUS
 CN Benzamide, N-3-[(1-ethyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-B

Me

RN 839706-76-2 CAPLUS
 CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-77-3 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-78-4 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-82-0 CAPLUS
 CN Acetamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-83-1 CAPLUS
 CN Acetamide, N-[3-(1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-84-2 CAPLUS
 CN Acetamide, N-[3-(1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839706-79-5 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-80-8 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-1,4-dihydro-7-(cyclopropylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-81-9 CAPLUS
 CN Acetamide, N-[3-(1-ethyl-1,4-dihydro-7-[(4-(4-morpholinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839706-85-3 CAPLUS
 CN Acetamide, N-[3-(7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)



RN 839706-86-4 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-7-[(1-ethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-87-5 CAPLUS
 CN Benzamide, N-[3-(7-(1,3-dimethyl-1H-pyrazol-5-yl)amino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-88-6 CAPLUS
 CN Benzamide, N-[3-(1-ethyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839706-89-7 CAPLUS
CN Benzamide, N-[3-[7-[(4,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-90-0 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-91-1 CAPLUS
CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-93-3 CAPLUS

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B



RN 839706-97-7 CAPLUS
CN Benzamide, N-[3-[7-[(5-[(dimethylamino)methyl]-2-thiazolyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 839706-98-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A


—CF₃

RN 839706-99-9 CAPLUS
CN Benzamide, N-[3-[7-[(4-[(dimethylamino)methyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[2-methyl-4-pyridinyl]amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-94-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-96-6 CAPLUS
CN Benzamide, N-[3-[7-[[4-[(2-(dimethylamino)ethyl)amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-00-5 CAPLUS
CN Benzamide, N-[3-[7-[(3-cyanophenyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-01-6 CAPLUS
CN Benzamide, N-[3-[7-[(5-cyano-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-02-7 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxypyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-03-8 CAPLUS
CN Benzamide, N-[3-[7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-04-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[(4-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-05-0 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-06-1 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-07-2 CAPLUS
CN Benzamide, N-[3-[7-(2,4-dimethyl-5-thiazolyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-08-3 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-09-4 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-10-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-11-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-12-9 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-13-0 CAPLUS
CN Benzamide, N-[3-[7-(methylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-14-1 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN INDEX NAME)


(Continued)



RN 839707-15-2 CAPLUS
CN Benzamide, N-[3-[(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-16-3 CAPLUS
CN Benzamide, N-[3-[(4-{2-(diethylamino)ethoxy}phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-B


 CF_3

RN 839707-17-4 CAPLUS
CN Benzamide, N-[3-[(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-18-5 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-19-6 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-1,4-dihydro-7-[(3-(4-morpholinyl)propyl]amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-20-9 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-1,4-dihydro-7-[(4-(4-morpholinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 839707-21-0 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-22-1 CAPLUS
CN Benzamide, N-[3-[(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-23-2 CAPLUS
CN Benzamide, N-[3-[(1-ethyl-1,4-dihydro-7-[(2-methyl-2-propenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-24-3 CAPLUS
CN Benzamide, N-[3-[(3-(diethylamino)propyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 839707-25 CAPLUS
CN Benzamide, N-[3-[(1-[(dimethylamino)phenyl]amino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-26-5 CAPLUS
CN Benzamide, N-[3-[(1-[(dimethylamino)phenyl]amino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-27-6 CAPLUS
CN Benzamide, N-[3-[(1-[(dimethylamino)phenyl]amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-nitro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-28-7 CAPLUS
CN Benzamide, 3-amino-N-[3-[(1-[(dimethylamino)phenyl]amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-29-8 CAPLUS
CN Benzamide, N-[3-[7-[(3-[(2S)-2-amino-1-oxopropyl]amino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

→CF₃


RN 839707-30-1 CAPLUS
CN Benzamide, N-[7-[(3-[(2S)-2-amino-3-methyl-1-oxobutyl]amino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A


PAGE 1-B



RN 839707-31-2 CAPLUS
CN Benzamide, N-[3-[7-[(6-[(3-(dimethylamino)-1-pyrrolidinyl)-3-pyridinyl]amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-32-3 CAPLUS
CN Benzamide, N-[3-[7-[(6-[(2-(dimethylamino)ethyl)methylamino)-3-pyridinyl]amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A


PAGE 1-B

→CF₃


RN 839707-33-4 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-pyrimidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 839707-34-5 CAPLUS
CN Benzamide, N-[3-[7-((5,6-dimethyl-1,2,4-triazin-3-yl)amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-36-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(pyrazinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839707-36-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-((3-methyl-5-isothiazolyl)amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-37-8 CAPLUS
CN Benzamide, N-[3-[7-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-38-9 CAPLUS
CN Benzamide, N-[3-[7-((1-ethyl-1H-pyrazol-5-yl)amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-39-0 CAPLUS
CN Benzamide, N-[3-[7-[(6-[2-(dimethylamino)-1-methylethoxy]-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CF3

RN 839707-40-3 CAPLUS
CN Benzamide, N-[3-[7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 839707-43-6 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-44-7 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-methyl-4-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-




RN 839707-45-8 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(5-(4-morpholinylmethyl)-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-46-9 CAPLUS
CN Benzamide, N-[3-[7-[(6-(diethylamino)-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-47-0 CAPLUS
CN Benzamide, N-[3-[7-[(6-(ethylamino)-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-48-1 CAPLUS
CN Benzamide, N-[3-[7-[(2,6-dimethyl-4-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-49-2 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-50-5 CAPLUS
CN Benzamide, N-[3-[7-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 839707-51-6 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-52-7 CAPLUS
 CN Benzamide, N-[3-[7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-53-8 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 839707-54-9 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 839707-58-3 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-59-4 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-60-7 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-55-0 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-56-1 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-5-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-57-2 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-61-8 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-(diethylamino)methyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-62-9 CAPLUS
 CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-63-0 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-64-1 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-65-2 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-66-3 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-67-4 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-68-5 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-69-6 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-70-9 CAPLUS
CN Benzamide, 4-[(cyclopropylamino)methyl]-N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-71-0 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-72-1 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-73-2 CAPLUS
CN Benzamide, N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-74-3 CAPLUS
CN Benzamide, 4-[(diethylamino)methyl]-N-[3-(1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-75-4 CAPLUS
CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 839707-76-5 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-77-6 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-78-7 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-79-8 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 839707-80-1 CAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-81-2 CAPLUS


CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-[3-(dimethylamino)-1-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-82-3 CAPLUS


CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-83-4 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-84-5 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-85-6 CAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(3-(dimethylamino)-1-pyrrolidinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 839707-86-7 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-87-8 CAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-95-8 CAPLUS

CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H-yl)-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)





IT 839707-96-9P 839707-97-0P 839707-98-1P
 839707-99-2P 839708-00-8P 839708-01-9P
 839708-02-0P 839708-03-1P 839708-04-2P
 839708-05-3P 839708-06-4P 839708-07-5P
 839708-08-6P 839708-09-7P 839708-10-0P
 839708-11-1P 839708-13-3P 839708-14-4P
 839708-15-5P 839708-16-6P 839708-17-7P
 839708-18-8P 839708-19-9P 839708-20-2P
 839708-21-3P 839708-22-4P 839708-23-5P
 839708-24-6P 839708-25-7P 839708-26-8P
 839708-27-9P 839708-28-0P 839708-29-1P
 839708-30-4P 839708-31-5P 839708-32-6P
 839708-33-7P 839708-34-8P 839708-35-9P
 839708-36-0P 839708-37-1P 839708-38-2P
 839708-39-3P 839708-40-6P 839708-41-7P
 839708-42-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidines as protein kinase inhibitors)


RN 839707-96-9 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 839708-00-8 CAPLUS
 CN Benzamide, N-[3-[7-[(2-fluoro-3-(trifluoromethyl)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-01-9 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-02-0 CAPLUS
 CN Benzamide, N-(3-[1,4-dihydro-1-methyl-7-[(3-[(methylsulfonyl)amino]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

--NMe₂


RN 839707-97-0 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-98-1 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(aminocarbonyl)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-99-2 CAPLUS
 CN Benzamide, N-[3-[7-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-03-1 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-[(methylsulfonyl)amino]phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




--Me


RN 839708-04-2 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)propyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-05-3 CAPLUS
 CN Acetamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 839708-06-4 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 839708-07-5 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 839708-08-6 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-2-thiazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 839708-09-7 CAPLUS
CN 4-Thiazoleacetic acid, 2-[[5,6,7,8-tetrahydro-8-methyl-6-[(2-methyl-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 839708-10-0 CAPLUS
CN Benzamide, N-[3-[(3-aminophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-11-1 CAPLUS
CN Benzamide, N-[3-[(7-(cyclohexylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-13-3 CAPLUS
CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-14-4 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-15-5 CAPLUS
CN Benzoic acid, 3-[[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 839708-16-6 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-2,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-17-7 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-18-8 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-19-9 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-20-2 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-21-3 CAPLUS
CN Benzamide, N-[3-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 839708-22-4 CAPLUS
CN Benzamide, N-[3-[(3-(hydroxyphenyl)amino)-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-23-5 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(3-(4-morpholinyl)sulfonyl)phenyl]amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-24-6 CAPLUS
CN Benzamide, N-[3-[(3-[(dimethylamino)methyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-25-7 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(3-(4-methyl-1-piperazinyl)sulfonyl)phenyl]amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



PAGE 1-B


--CF₃

RN 839708-26-8 CAPLUS
CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(2-(4-methyl-1-piperazinyl)-4-pyridinyl]amino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-27-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[(3-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methyl-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



Absolute stereochemistry.




RN 839708-29-1 CAPLUS
CN Benzamide, N-[3-[(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-30-4 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-31-5 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-32-6 CAPLUS
 CN Benzamide, N-[3-[7-[(6-(dimethylamino)-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-33-7 CAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-36-0 CAPLUS
 CN Benzamide, 3-[(acetamido)-N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-37-1 CAPLUS
 CN Benzamide, 3-[(2-(dimethylamino)ethoxy)-N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-38-2 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-[2-(4-morpholinyl)ethoxy]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PAGE 1-A




PAGE 1-B

RN 839708-34-8 CAPLUS
 CN Benzamide, N-[3-[7-[[3-[(2-(dimethylamino)ethyl)amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-B




RN 839708-35-9 CAPLUS
 CN Benzamide, N-[3-[7-[(5-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PAGE 1-A




PAGE 1-B



RN 839708-39-3 CAPLUS
 CN Benzamide, 3-[(2-(dimethylamino)ethyl)amino]-N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-40-6 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-41-7 CAPLUS


L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-42-8 CAPLUS
 CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 839708-47-3 839708-49-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrimidopyrimidines as protein kinase inhibitors).
 RN 839708-47-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-(dimethylamino)phenyl)amino]-3,4-dihydro-1-methyl-3-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 839708-48-4 CAPLUS

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ACCESSION NUMBER: 2004:857176 CAPLUS
 DOCUMENT NUMBER: 141:350187
 TITLE: Preparation of pyrimido compounds having antiproliferative activity
 INVENTOR(S): Chen, Yi; Dermatasikis, Apostolos; Liu, Jin-jun; Luk, Kian-chun; Michoud, Christophe; Rossman, Pamela Loreen
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 55 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|-----------------|------------|
| US 2004204427 | A1 | 20041014 | US 2004-817697 | 20040402 |
| WO 2004089955 | A1 | 20041021 | WO 2004-EP3447 | 20040401 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: | | US 2003-461694P | | P 20030410 |
| OTHER SOURCE(S): | | MARPAT 141:350187 | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are methods for preparing novel pyrimido compds. I [R1 = H, (un)substituted-alkyl, -cycloalkyl, -alkynyl, etc.; R2 and R3 independently = H, halo, (un)substituted-alkyl, -alkenyl, etc.; R4-8 independently = H, hydroxymethyl, alkoxymethyl, halo, etc.] that are selective inhibitors of both KDR and FGFR kinases. Thus, e.g., II was prep'd via acylation of trans-4-(tert-Butyldimethylsilyloxy)cyclohexylamine (preparation given) with phosgene and subsequent cyclization with (2,4-dichloropyrimidin-5-ylmethyl) (4-methoxyphenyl)amine followed by desilylation. The IC50 values for I were as follows: KDR less than 0.50 μ M; FGFR less than 2 μ M. These compds. and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compds. containing these compds. and methods of treating cancer.


IT 774232-16-5P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionitrile
 774232-32-5P, 4-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 774232-33-6P, trans-1-[4-(tert-Butyldimethylsilyloxy)cyclohexyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-34-7P,

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(5-amino-2-methylphenyl)-7-[(3-(dimethylamino)phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-1-yl)piperidine-1-carboxylic acid tert-butyl ester 774232-35-9P, cis-1-[3-(tert-Butyldimethylsilyloxy)cyclopentyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-44-9P 774232-45-0P 774232-49-3P
 774232-50-7P 774232-55-2P 774232-58-5P
 774232-60-9P 774232-61-0P 774232-62-1P
 774232-63-2P 774232-64-3P 774232-68-7P
 774232-71-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of pyrimido[4,5-d]pyrimidones as selective inhibitors of both KDR and FGFR kinases).

RN 774232-16-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanenitrile, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-32-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 774232-33-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



Relative stereochemistry.




Relative stereochemistry.



Absolute stereochemistry. Rotation (-).




Relative stereochemistry.




Relative stereochemistry.


Absolute stereochemistry. Rotation (-).



Relative stereochemistry.




Relative stereochemistry.




RN 774232-61-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-62-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-63-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-64-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(4-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-68-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 774232-71-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3R)-3-[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclopentyl]-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




IT 774231-91-3P, 1-Cyclohexyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-92-4P,
3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-4-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-93-5P,
1-(trans-4-Hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-94-6P,
3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-3-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-95-7P,
1-Cyclopentyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-96-8P,
1-(1,1-Dioxo-tetrahydro-1H-phenanthren-3-yl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-97-9P,
3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxaldehyde 774231-98-0P,
3-(4-Methoxyphenyl)-7-phenylamino-1-(tetrahydro-pyran-4-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-99-1P,
1-(trans-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-00-7P,
1-(cis-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-01-8P,
(R)-3-(4-Methoxyphenyl)-7-phenylamino-1-(tetrahydrofuran-3-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-02-9P,
(R)-3-(4-Methoxyphenyl)-7-phenylamino-1-(pyrrolidin-3-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-03-0P,
trans-7-(4-Fluorophenylamino)-1-(3-hydroxycyclopentyl)-3-(4-methoxyphenyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-04-1P,
trans-3-(2-Fluoro-4-methoxyphenyl)-1-(3-hydroxycyclopentyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-05-2P,
(S)-(+) 1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-06-3P,
(S)-(+) 7-(4-Fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-07-4P, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-08-5P, trans-3-(2-Fluoro-4-methoxyphenylamino)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-09-6P, trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-10-9P, trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-11-0P, (S)-(+) 3-(2-Fluoro-4-methoxyphenyl)-7-(4-methoxyphenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-12-1P, (S)-(+) 3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-13-2P, (R)-(+) 1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-14-3P, 3-(4-Methoxyphenyl)-1-methyl-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-15-4P, 1-(2-Methoxyethoxyethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-16-5P, (S)-(+) 3-(2-Fluoro-4-methoxyphenyl)-7-(4-methoxyphenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-17-6P, 774232-18-7P, (R)-1-(2-Hydroxypyropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-19-8P, 774232-21-2P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionamide 774232-22-3P, (S)-(+) 1-(2-Hydroxypyropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-23-4P, 774232-24-5P, 774232-25-6P, 774232-26-7P, 774232-27-8P, 774232-28-9P

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 774232-29-0P, (R)-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 774232-30-3P, trans-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(3-hydroxycyclopentyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 RI: PAC (Pharmacological activity); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)

RN 774231-91-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclohexyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774231-92-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 774231-93-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774231-94-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 774231-95-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774231-96-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 774231-97-9 CAPLUS
 CN 1-Piperidinecarboxaldehyde, 3-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 774231-98-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 774231-99-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-00-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-01-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-[(3R)-tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 774232-02-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 774232-03-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-04-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-05-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 774232-06-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 774232-07-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-{(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-08-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-09-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-10-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774232-11-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-12-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 774232-13-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 774232-14-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774232-15-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2-methoxyethyl)methyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




Absolute stereochemistry. Rotation (+).




Absolute stereochemistry.




Absolute stereochemistry. Rotation (-).




RN 774232-21-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanamide, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)




Absolute stereochemistry. Rotation (+).



Relative stereochemistry.




Relative stereochemistry.



L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 774232-25-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-26-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-27-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 774232-28-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1a,3a,5a)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-29-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 774232-30-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-31-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(cyclopropylmethyl)-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




IT 774232-74-5P 774232-75-6P 774232-78-9P
 774232-79-0P 774232-80-3P 774232-86-9P
 774232-90-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 774232-74-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-75-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-78-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-79-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)diphenylsilyloxy]-1-methylethyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-80-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[(1,1-dimethylethyl)diphenylsilyloxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774232-86-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2R)-2-[(1,1-dimethylethyl)diphenylsilyloxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 774232-90-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2S)-2-[(1,1-dimethylethyl)diphenylsilyloxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2004-701815 CAPLUS

DOCUMENT NUMBER: 141:185104

TITLE: Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions

INVENTOR(S): Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar

PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 107 pp.

SOURCE: CODEN: USXKCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 2004167197 | A1 | 20040826 | US 2004-788220 | 20040226 |
| WO 2004075852 | A2 | 20040910 | WO 2004-US5609 | 20040226 |
| | | | | |
| W: AE, AG, AL, AL, AM, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CO, CO, CR, CU, CU, CZ, CZ, DE, DE, DK, DM, DZ, EC, EC, EE, EG, ES, FI, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MG, MN, MW, MX, MX, MZ, NA, NI | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2004075857 | A2 | 20040910 | WO 2004-US5799 | 20040226 |
| | | | | |
| W: AE, AG, AL, AM, AM, AT, AT, AU, A2, AZ, BA, BB, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CO, CO, CR, CU, CU, CZ, CZ, DE, DE, DK, DM, DZ, EC, EC, EE, EG, ES, FI, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MG, MN, MW, MX, MX, MZ, NA, NI | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |


PRIORITY APPLN. INFO.: US 2003-450529P P 20030226
AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.

IT 335652-44-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (comprns., combinations, and methods for treating cardiovascular
 conditions and other assocd. conditions)
 RN 335652-44-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
 [(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 (Continued)
 ACCESSION NUMBER: 2004-633921 CAPLUS
 DOCUMENT NUMBER: 141:174079
 TITLE: Preparation of 2-aminopyridines as cdk4 inhibitors
 INVENTOR(S): Biwersi, Cathlin Marie; McNamara, Dennis Joseph;
 Repine, Joseph Thomas; Toogood, Peter Laurence;
 Vandervel, Scott Norman; Warmus, Joseph Scott
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004065378 | A1 | 20040805 | WO 2004-1891 | 20040109 |
| W: AE, AR, AG, AL, AM, AM, AT, AT, AU, AZ, AZ, BA, BB,
BG, BG, BR, BR, BY, BY, BZ, BZ, CA, CH, CN, CO, CO, CR,
CR, CU, CU, CZ, CZ, DE, DE, DK, DM, DZ, EC, EC, EE, EG,
ES, ES, FI, FI, GB, GD, GE, GH, GH, GM, HR, HR, HU, HU,
ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ,
KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN,
MW, MX, MX, MZ | | | | |
| US 2004236084 | A1 | 20041125 | US 2004-759749 | 20040116 |
| PRIORITY APPLN. INFO.: US 2003-440805P | | | US 2003-440805P | P 20030117 |
| OTHER SOURCE(S): MARPAT 141:174079 | | | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (wherein A1 = (un)substituted monocyclic or bicyclic heteroaryl; R1 = H, alk(en)yl, acyl, aryloxycarbonyl, alkoxycarbonyl, trialkylsilyl; X, Y = independently H, halo, CN, alkyl, alkylcarbonyl, alkoxycarbonyl, NO2, OH and derivs., NH2 and derivs., SO2NH2 and derivs., etc.; W = H, halo, cyclo/alkoxy/halo/hydroxy/alkyl, alkenyl, alkynyl, CN, NO2, SH and derivs., NH2 and derivs., SO2NH2 and derivs., heteroaryl, etc.; WCCY, or WCCY = (un)substituted aryl ring containing up to three heteroatoms; and their pharmaceutically acceptable salts, esters, amides, or prodrugs) were prepared as cyclin-dependent kinases 4 (cdk4) inhibitors. For example, II was prepared by cyclocondensation of guanidine III with 2-Cyclopentyl-6-hydroxymethylene-3-methoxycyclohex-2-en-1-one, dehydrogenation, and BOC-deprotection. II selectively inhibited cdk4 over cdk2 with IC50 values of 0.004 μ M and 1.7 μ M, resp. Thus, I and their formulations are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis (no data).
 IT 733039-10-6P, 3-Benzyl-1-cyclopentyl-7-[{3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-yl}amino]-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (treating cell proliferative disorders)
 RN 733039-10-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3,4-dihydro-3-
 (phenylmethyl)-7-[[5-(1-piperidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX
 NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 (Continued)
 ACCESSION NUMBER: 2004-412946 CAPLUS
 DOCUMENT NUMBER: 140:423694
 TITLE: Preparation of pyrimidopyrimidinone derivatives having
 anticancer activity
 INVENTOR(S): Dermatasik, Apostolos; Kabat, Marek Michal; Luk,
 Klin-Chun Rossman, Pamela Loreen; So, Sung-Sau
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 200401822 | A1 | 20040521 | WO 2003-EP11896 | 20031027 |
| W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, U2, UC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZV, AM, AZ, BY,
KG, KZ, MD, RU, TZ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 200410773 | A1 | 20040610 | US 2003-689438 | 20031020 |
| US 2005075272 | A1 | 20050407 | US 2003-689235 | 20031020 |
| PRIORITY APPLN. INFO.: MARPAT 140:423694 | | | US 2002-423670P | P 20021104 |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I (R1 = H, (substituted)alkyl, (substituted)acyl, (substituted)heteroaryl, (substituted)heterocycle, (substituted)cycloalkyl, (substituted)alkenyl, (substituted)alkynyl; R2, R3, R4 = H, halo, COR10, CO2R10, CONR10R11, SOR10, SO2R10, CN, or NO2; R5, R6, R7, R8 = H, (substituted)alkyl, (substituted)amino, OH, halo, etc.; R9 = H, -COCR12R13OCOR14, or COR15; R10, R11 = H, (substituted)alkyl, (substituted)cycloalkyl, (substituted)heterocycle, etc.; R12, R13 = H, alkyl; R14 = (substituted)alkyl; R15 = H, alkyl or cycloamines with 3-7 atoms) were prepared as anti-proliferative agents for the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. For example, reaction of 7-chloro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-3,4-dihydro-1H-pyrimido[4,5-d]2-one (preparation given) with aniline yielded compound II. The latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC50 < 10 μ M.
 IT 690991-80-1P 690991-82-3P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidopyrimidinone derivs. having anticancer activity)


RN 690991-80-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.




RN 690991-82-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 690991-78-7P 690991-94-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USSES (Uses)
 (preparation of pyrimidopyrimidinone derivs. having anticancer activity)
 RN 690991-78-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-94-7 CAPLUS
 CN Benzonitrile, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 690991-84-5P 690991-86-7P 690991-88-9P
 690991-90-3P 690991-92-5P 690991-96-9P
 690991-98-1P 690992-00-8P 690992-02-0P
 690992-04-2P 690992-06-4P 690992-12-2P
 690992-14-4P 690992-16-6P 690992-17-7P
 690992-19-9P 690992-21-3P 690992-23-5P
 690992-25-7P 690992-27-9P 690992-29-1P
 690992-30-4P 690992-32-6P 690992-34-8P
 690992-36-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidopyrimidinone derivs. having anticancer activity)
 RN 690991-90-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1,3-bis(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-86-7 CAPLUS
 CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 690991-88-9 CAPLUS
 CN Benzamide, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-90-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 4-ethyl-3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-92-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690991-96-9 CAPLUS
 CN Benzamide, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690991-98-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-(1-methylethyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690992-00-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-5-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 690992-02-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-04-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 690992-06-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 690992-17-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690992-19-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 690992-12-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-1-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690992-14-4 CAPLUS
 CN Acetamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-5-methyl-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 690992-16-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

















RN 690992-21-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-23-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|------------|
| WO 2004041821 | A1 | 20040521 | WO 2003-EP311892 | 20031027 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004110773 | A1 | 20040610 | US 2003-689438 | 20031020 |
| US 2005075272 | A1 | 20050407 | US 2003-689235 | 20031020 |
| PRIORITY APPLN. INFO.: | | | US 2002-423670P | P 20021104 |
| OTHER SOURCE(S): | | | MARPAT 140:423693 | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB: MovPyrimido compds. I (R1 = H, alkyl, substituted alkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkenyl, alkynyl; R2, R3, R4 independently = H, amine, alkoxy, sulfamyl, alkyl, cycloalkyl, alkenyl, alkynyl; R5, R6, R7, R8 independently = H, lower alkyl, amine, OH, alkoxy, sulfamyl, halogen, ketone, ester, amide, sulfonyl, CN; R9 = H, diester, ketone), that are selective inhibitors of the Src family of tyrosine kinases are prepared for the treatment of breast, colon, pancreatic, and hepatic cancers. Thus, 1-(2,4-dichloro-pyrimidin-5-yl)-ethanol was treated with phosphorus oxybromide and diisopropyl amine to give 2,4-dichloro-5-(1-bromoethyl)-pyrimidine which was treated with p-anisidine, potassium carbonate, and potassium iodide to give the corresponding amine. The above amine was reacted with 3-cyanophenyl isocyanate in toluene to give II. II was reacted with acetic acid 2-(3-amino-phenyl)-Et ester, followed by treatment with potassium carbonate in methanol to give III. III showed and IC50 of less than 1.0 μ M against Src tyrosine kinase. Also disclosed are pharmaceutical compns. containing these compds. and the use for


treating cancer.

IT 690995-25-6P 690995-29-0P 690995-31-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)


RN 690995-25-6 CAPLUS

CN Benzonitrile, 3-[{3-[2-(dimethylamino)ethyl]phenyl}amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl - (9CI) (CA INDEX NAME)




RN 690995-29-0 CAPLUS

CN Benzonitrile, 3-[{3-[2-hydroxyethyl]phenyl}amino]-3-(4-methoxyphenyl)-4-methyl-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl - (9CI) (CA INDEX NAME)




RN 690995-31-4 CAPLUS

CN Benzonitrile, 3-[{3-[2-(diethylamino)ethyl]phenyl}amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl - (9CI) (CA INDEX NAME)



RN 690995-33-6 CAPLUS

CN Benzonitrile, 3-[{3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[{3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl}amino]-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl}- (9CI) (CA INDEX NAME)




IT 690995-35-8P 690995-36-9P 690995-37-0P

690995-38-1P 690995-39-2P 690995-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)


RN 690995-35-8 CAPLUS

CN Benzamide, 3-[{3-[2-(diethylamino)ethyl]phenyl}amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl - (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 showed IC₅₀ of 7.5 nM against src kinase, and IC₅₀ of 6.3 nM against lck kinase. The pharmaceutical compn. contg. the compd. I is claimed.
 IT 686756-67-6P 686756-91-2P 686756-98-9P
 RN 686757-21-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)


RN 686756-87-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-91-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2-(chloromethyl)-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-98-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-[(4-methylphenyl)sulfonyloxy)methyl]-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686757-02-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2-(dimethylamino)methyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-06-2 CAPLUS
 CN Spiro[1,3-benzodioxole-2,4'-piperidine], 1'-acetyl-5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686757-10-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidine]-5-ylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 686757-21-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




IT 686756-95-6P 686757-02-8P 686757-06-2P
 686757-10-5P 686757-14-2P 686757-17-5P
 686757-25-5P 686757-29-9P 686757-33-5P
 686757-37-9P 686757-40-4P 686757-44-8P
 686757-48-2P 686757-55-11P 686757-60-8P
 686757-65-3P 686757-70-0P 686757-73-3P
 686757-78-8P 686757-82-4P 686757-88-0P
 686757-93-7P 686759-58-0P 686759-62-6P
 686759-66-0P 686759-70-6P 686759-74-0P
 686759-78-4P 686759-82-0P 686759-86-4P
 686759-92-2P 686759-99-9P 686760-03-2P
 686760-07-6P 686760-11-2P 686760-14-5P
 686760-18-9P 686760-22-5P 686760-26-9P
 686760-30-5P 686760-34-9P 686760-37-2P
 686760-41-0P 686760-47-4P 686760-51-0P
 686760-55-4P 686760-59-8P 686760-63-4P
 686760-67-8P 686760-70-3P 686760-74-7P
 686760-78-1P 686760-82-7P 686760-92-9P
 686760-96-3P 686761-00-2P 686761-07-9P
 686761-11-5P 686761-18-2P 686761-21-7P
 686761-25-1P 686761-29-5P 686761-36-4P
 686766-23-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)

RN 686756-95-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 686757-14-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-4-dioxido-1,4-benzothiathien-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-17-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4-dioxido-1,4-benzothiathien-6-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 686757-25-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[(3-methoxy-4-methyl-1-oxido-4H-1,4-benzothiathien-7-yl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-29-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-2H-1,4-benzothiathien-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-33-5 CAPLUS
CN 1H-Isindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-(2-hydroxy-1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 686757-37-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)- (9CI) (CA INDEX NAME)




RN 686757-40-4 CAPLUS
CN 1H-Isindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





RN 686757-60-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-65-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-7-((2,3-dihydro-4,4-dioxido-1,4-benzothiazin-6-yl)amino)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-70-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-methoxyphenyl)-7-((2,3-dihydro-4,4-dioxido-1,4-benzothiazin-6-yl)amino)-3-(2-fluoro-6-methoxyphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




• HCl

RN 686757-44-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-((3,3-dioxido-1,3-dimethyl-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-2-yl)amino)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 686757-48-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-((1,3-benzodioxol-5-ylamino)-3,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-2-yl)amino)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 686757-55-1 CAPLUS
CN 1H-Isindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


RN 686757-73-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-((2,3-dihydro-4,4-dioxido-1,4-benzothiazin-6-yl)amino)-3,4-dihydro-1,4-dimethyl-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-78-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-((3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino)-3,4-dihydro-1,4-dimethyl-, (4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-82-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-((3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino)-3,4-dihydro-1,4-dimethyl-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 686757-88-0 CAPLUS
CN Benzonitrile, 2-[(7-((2,3-dihydro-4,4-dioxido-1,4-benzothiazin-6-yl)amino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 686757-93-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-58-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(1,3-benzodioxol-5-ylamino)-3-(2,4-dichlorophenyl)-3,4-dihydro-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 686759-62-6 CAPLUS
CN Benzonitrile, 2-[7-(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl - (9CI) (CA INDEX NAME)





RN 686759-78-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(1'-ethylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-82-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[(1'-methyl-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-86-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-7-[(1'-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-66-0 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 686759-70-6 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-acetyl-5-[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686759-74-0 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 686759-99-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-[(1'-methyl-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 686760-03-2 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-acetonitrile, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686760-07-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-3,4-dihydro-1-methyl-7-[(1'-2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino]- (9CI) (CA INDEX NAME)




RN 686760-11-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-14-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-18-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-22-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-26-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-30-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2-[(cyclopropylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-34-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-37-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-41-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-47-4 CAPLUS




RN 686760-51-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-55-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-59-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-1,4-benzodioxin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-63-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-67-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-70-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-74-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,4-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-78-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1-oxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-82-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1-oxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-92-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-96-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-00-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-07-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-18-2 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 686761-21-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 686761-25-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-[[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686761-29-5 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-[[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 686761-36-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,3-dioxido-1,3-benzoxathiol-5-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686766-23-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ACCESSION NUMBER: 2004:162462 CAPLUS
DOCUMENT NUMBER: 140:199340
TITLE: Preparation of pyrimidopyrimidinone derivatives having antiproliferative activity
INVENTOR(S): Chen, Yi; Daniewski, Andrzej Robert; Harris, William; Kabat, Marek Michal; Liu, Emily Ajuns; Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 2004038995 | A1 | 20040226 | US 2003-623972 | 20030721 |
| WO 2004018472 | A2 | 20040304 | WO 2003-EP8744 | 20030807 |
| WO 2004018472 | A3 | 20040429 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-403519 P 20020814
OTHER SOURCE(S): MARPAT 140:199340
GI | | | | |




AB The title I [R1 = H, COR4, COOCH(R5)OCO4; R2, R3 = H or OR5; R4 = alkyl, or alkyl substituted by NR5R6, SR5, OR5, (substituted)aryl, heteroaryl, heterocycle; R5, R6 = H, alkyl or NR5R6 form a ring optionally including one or more addnl. N or O] were prepared as selective inhibitors of both KDR and FGFR kinases and are selective against LCK. Thus, reaction of 7-chloro-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimido[4,5-d]2-one (preparation given) with aniline yielded compound II (R1, R2, R3 = H). The

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC50 = 0.044, 0.076, 0.360, and 0.130 μ M, resp.
IT 663198-02-3P 663198-06-9P 663198-08-1P
663198-09-2P 663198-20-7P 663198-27-4P
663198-33-2P 663198-34-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses);
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)
RN 663198-02-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 663198-06-9 CAPLUS
CN Glycine, N,N-dimethyl-, [[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)



RN 663198-08-1 CAPLUS
CN Acetamide, 2-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-07-0
CMF C27 H24 N6 O3



CM 2


CRN 64-19-7

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C2 H4 O2




RN 663198-09-2 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663198-20-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-[4-(4-methoxyphenyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-27-4 CAPLUS
CN Benzenepropanamide, α -amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 663198-03-6 CAPLUS
CN Acetamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 663198-04-7 CAPLUS
CN Propanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-05-8 CAPLUS
CN Carbamic acid, phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (acetyloxy)methyl ester (9CI) (CA INDEX NAME)




RN 663198-10-5 CAPLUS
CN Benzenepropanamide, α -amino-4-hydroxy-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 663198-33-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl-N- [5,6,7,8-tetrahydro-3-(4-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-34-3 CAPLUS
CN Acetamide, N-[4-[(1,1-dimethylsilyl)dimethylsilyl]oxy]phenyl-N- [5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



IT 663198-03-6P 663198-04-7P 663198-05-8P
663198-10-5P 663198-11-6P 663198-12-7P
663198-13-8P 663198-15-0P 663198-16-1P
663198-17-2P 663198-18-3P 663198-19-4P
663198-21-8P 663198-22-9P 663198-23-0P
663198-24-1P 663198-25-2P 663198-26-3P
663198-28-5P 663198-30-9P 663198-31-0P
663198-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidone derivs. having antiproliferative activity)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 663198-11-6 CAPLUS
CN Hexanamide, 2,6-diamino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 663198-12-7 CAPLUS
CN 1H-Indole-3-propanamide, α -amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 663198-13-8 CAPLUS

CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 663198-15-0 CAPLUS

CN 4-Piperidinocarboxylic acid, [[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyloxy]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 663198-14-9

CNF C33 H32 N6 O6




CM 2

CRN 76-05-1
CNF C2 H F3 O2


RN 663198-16-1 CAPLUS

CN Pentanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-17-2 CAPLUS

CN Butanamide, N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-18-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(4-hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-19-4 CAPLUS

CN Acetamide, N-(4-hydroxyphenyl)-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 663198-21-8 CAPLUS

CN Acetamide, N-(4-methoxyphenyl)-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 663198-22-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 663198-02-5

CNF C25 H21 N5 O2



CM 2


CRN 75-75-2

CNF C H4 O3 S



RN 663198-23-0 CAPLUS


CN Glycine, N,N-dimethyl-, [[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyloxy]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 663198-24-1 CAPLUS

CN Acetamide, 2-amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 663198-25-2 CAPLUS


CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-09-2

CNF C30 H30 N6 O3 S

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 663198-26-3 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 663198-28-5 CAPLUS
CN Benzenepropanamide, α -amino-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (α S)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● HCl


RN 663198-32-1 CAPLUS
CN Propanamide, 2-amino-3-hydroxy-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 663198-38-7P 663198-39-8P 663198-41-2P
663198-42-3P 663198-44-5P 663198-46-7P
663198-47-6P 663198-48-9P 663198-50-3P
663198-51-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidone derivs. having antiproliferative activity)
RN 663198-38-7 CAPLUS
CN Carbamic acid, phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, chloromethyl ester (9CI) (CA INDEX NAME)




● HCl

RN 663198-30-9 CAPLUS
CN Pentanamide, 2-amino-4-methyl-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 663198-29-6
CMF C31 H32 N6 O3


Absolute stereochemistry.



CM 2


CRN 64-19-7
CMF C2 H4 O2

RN 663198-31-0 CAPLUS
CN Pentanamide, 2-amino-4-methyl-N-phenyl-N-[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]-, (2S)-,




RN 663198-39-8 CAPLUS
CN Carbamic acid, [(1S)-3-(methylthio)-1-[(phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663198-41-2 CAPLUS
CN Carbamic acid, [(1S)-2-oxo-2-[(phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino)-1-(phenylmethyl)ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 663198-42-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[(phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]butyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-44-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[(4-(1,1-dimethylethoxy)phenyl)methyl]-2-oxo-2-phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663198-46-7 CAPLUS


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]phenylamino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-50-3 CAPLUS
 CN Carbamic acid, [(1R)-3-(methylthio)-1-[[[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]phenylamino]carbonyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663198-51-4 CAPLUS
 CN 1,4-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl)-4-[[[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]oxy]methyl] ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Carbamic acid, [(1S)-1-[[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]carbonyl]-1,5-pentanediyli]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663198-47-8 CAPLUS
 CN Carbamic acid, [(1S)-1-(1H-indol-3-ylmethyl)-2-oxo-2-[phenyl[5,6,7,8-tetrahydro-6-(4-methoxyphenyl)-7-oxo-8-phenylpyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663198-48-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[(1,1-dimethylethoxy)methyl]-2-oxo-2-[[5,6,7,8-



L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:80385 CAPLUS
 DOCUMENT NUMBER: 140:146153
 TITLE: Preparation of pyrimidopyrimidinones as kinase inhibitors
 INVENTOR(S): Chivikas, Connolly Cleo J.; Deur, Christopher James; Hamby, James Marion; Hoyer, Denton Wade; Limberakis, Chris; Reed, Jessica Elizabeth; Schroeder, Mel Conrad; Taylor, Clacke
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| US 2004019210 | A1 | 20040129 | US 2003-621983 | 20030717 |
| WO 2004011465 | A1 | 20040205 | WO 2003-IB3359 | 20030721 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MV, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: MARPAT 140:146153 | | | US 2002-398638P | P 20020725 |
| OTHER SOURCE(S): GI | | | | |

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

II

AB This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimidopyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula I [A = O, NH₂, mono(or di)alkylamino, NHCONHR₁₂ (wherein R₁₂ = alkyl, alkenylenealkyl); B, C, D = CH, N (with the proviso that C and D are not both N); R₁ = alkyl (optionally substituted with CO₂H), (un)substituted Ph, CH₂Ph, piperidinyl, etc.; R₂ = H, Cl; R₃ = H, Cl, F (at least one of R₂ or R₃ = F); R₄ = H, OH, OMe, OEt (if R₄ = H, R₂ and R₃ is not H); R₅ = OMe, OEt; R₆ = H, alkyl-NH₂, O-alkyl-NH₂, etc.] that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediates for their synthesis, as well as pharmaceutical compns. and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer (no biol. data given). Synthesis of 35 title compds. I is described. E.g., a multi-step synthesis of II was given.


IT 651734-15-5 CAPLUS

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-15-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(4-(diethylamino)butyl)amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-16-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[4S,5S]-5-(hydroxymethyl)-2-phenyl-1,3-dioxolan-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-35-9 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylenamino)-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 651734-22-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylenamino)-2-oxypyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 651734-14-4P 651734-17-7P 651734-18-6P

651734-19-9P 651734-20-2P 651734-21-3P

651734-22-4P 651734-23-5P 651734-24-6P

651734-25-7P 651734-26-8P 651734-27-9P

651734-28-0P 651734-29-1P 651734-30-4P

651734-31-5P 651734-32-6P 651734-33-7P

651734-34-8P 651734-36-0P 651734-38-2P

651734-39-3P 651734-40-6P 651734-41-7P

651734-42-8P 651734-45-1P 651734-46-2P


651734-47-3P 651734-48-4P 651734-49-5P

651734-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-14-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(4-(diethylamino)butyl)amino]-3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-17-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-18-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-19-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxy-1-hydroxymethyl)ethylamino]- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-20-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-21-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxyethoxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 651734-22-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-7-[(4-diethylamino)butyl]amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-23-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-diethylamino)butyl]amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-24-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(2-hydroxy-1-hydroxymethyl)ethylamino]- (9CI) (CA INDEX NAME)



RN 651734-25-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-26-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-27-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 651734-28-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[(4-amino-2,3-dihydroxybutyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-29-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-30-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(2-(2-hydroxyethoxy)ethyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-31-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(2S,3S)-4-amino-2,3-dihydroxybutyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-32-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(bis(2-hydroxyethyl)amino)propyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-33-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2S)-2,3-dihydroxypropyl]amino-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-34-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-36-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 651734-37-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-37-1

CMF C19 H22 F2 N6 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 651734-39-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxymethyl)ethyl]amino- (9CI) (CA INDEX NAME)




RN 651734-40-6 CAPLUS

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-hydroxybutyl)amino]- (9CI) (CA INDEX NAME)



RN 651734-41-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2S)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-42-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

RN 651734-43-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-47-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(4-diethylamino)butyl]amino]-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-48-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2R)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 651734-45-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-44-0
 CMF C20 H24 F2 N6 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 651734-46-2 CAPLUS

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 651734-49-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxyethoxy)ethyl]amino- (9CI) (CA INDEX NAME)




RN 651734-50-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 651735-19-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (prepns of pyrimidopyrimidinones as kinase inhibitors)
 RN 651735-18-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 (Continued)
 2003:651919 CAPLUS
 DOCUMENT NUMBER: 140:16695
 TITLE: Solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones
 AUTHOR(S): Gravelaud, Nadege; Masquelin, Thierry
 CORPORATE SOURCE: Combinatorial & Parallel Chemistry, Basilea Pharmaceutica Ltd., Basel, 4002, Switz.
 SOURCE: Synthesis (2003), (11), 1739-1743
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:16695

AB The authors report a novel and versatile solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones starting from the polymer-bound Et 4-amino-2-sulfanylpyrimidine-5-carboxylate. The key step is based on the reaction of the support-bound pyrimidine with isocyanates, involving formation of a carbamate intermediate, followed by a base-catalyzed intramolecular ring closure, to give polymer-bound 3-monosubstituted 1H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones. At this stage, subsequent treatment with alkyl halides led to 1,3-disubstituted 2H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione intermediates, which after oxidation and cleavage with various amines gave 1,3-disubstituted 7-amino-2H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones in moderate yields and high purity.

IT 630394-21-7P 630394-23-PP 630394-24-OP
 630394-25-1P 630394-27-3P 630394-28-4P
 630394-29-5P 630394-30-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones)
 RN 630394-21-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1-(cyclopropylmethyl)-3-(2-fluorophenyl)-7-[(3-(4-morpholinyl)propyl)amino]- (9CI) (CA INDEX NAME)



RN 630394-23-9 CAPLUS
 CN Benzoic acid, 3-[1-(3-cyanopropyl)-1,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 630394-24-0 CAPLUS
 CN Benzoic acid, 3-[1-[(3-fluorophenyl)methyl]-1,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)


RN 630394-25-1 CAPLUS
 CN Benzoic acid, 3-[1-[(4-cyanophenyl)methyl]-1,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 630394-27-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxo-a-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 630394-28-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-3(2H)-acetic acid, 1-[(4-cyanophenyl)methyl]-1,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxo-a-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 630394-29-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-2,4-dioxo-a-(phenylmethyl)-7-[(2-pyridinyl)ethyl]amino-, ethyl ester, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 630394-30-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanoic acid, 3-[(1S)-2-ethoxy-2-oxo-1-(phenylmethyl)ethyl]-3,4-dihydro-7-[(3-(4-morpholinyl)propyl)amino]-2,4-dioxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p38 protein kinase

INVENTOR(S): Dunn, James Patrick; Fisher, Lawrence Emerson; Goldstein, David Michael; Harris, William; Hill, Christopher Huw; Smith, Ian Edward David; Welch, Teresa Rosanne

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz. PCT Int. Appl., 177 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-------------------|----------|
| WO 2001029042 | A1 | 20010426 | WO 2000-EP10088 | 20001013 |
| W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW AM AZ BY KG KZ MD RU TJ TM RW GH KE LS MW SD SL SZ TZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG | | | | |
| CA 2388142 | AA | 20010426 | CA 2000-2388142 | 20001013 |
| BR 2000015243 | A | 20020716 | BR 2000-15243 | 20001013 |
| EP 1228070 | A1 | 20020807 | EP 2000-967864 | 20001013 |
| R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE MC PT IE SI LT LV FI RO MK CY AL | | | | |
| TR 200201057 | T2 | 20020923 | TR 2002-200201057 | 20001013 |
| JP 2003512378 | T2 | 20030402 | JP 2001-531840 | 20001013 |
| NZ 518119 | A | 20040227 | NZ 2000-518119 | 20001013 |
| AU 776250 | B2 | 20040902 | AU 2000-77873 | 20001013 |
| US 6451804 | B1 | 20020917 | US 2000-693337 | 20001020 |
| ZA 2002002540 | A | 20030630 | ZA 2002-2540 | 20020328 |
| NO 2002001781 | A | 20020418 | NO 2002-1781 | 20020416 |
| PRIORITY APPLN. INFO.: | | | | |
| US 1999-160803P | P | | 19991021 | |
| US 2000-213743P | P | | 20000622 | |
| WO 2000-EP10088 | W | | 20001013 | |

OTHER SOURCE(S): MARPAT 134:326540

GI



AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl, alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclic, etc.; R4 = H, alkyl, etc.; n = 0-3], were prepared for pharmaceutical use. The compds. are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NHCH2CH2OH, R3 = Me) was prepared via a substitution reaction of H2NCMe2CH2OH with sulfone II (R = SO2Me, R3 = Me) when combined and heated to 100-110° for 1 h. The prepared dihydropyrimido[4,5-d]pyrimidinone derivs. showed 50% p38 inhibitory activity at concns. < 10 μM.

IT 335651-19-29 335651-20-29 335651-24-6

335651-30-4P 335651-49-5P 335651-50-8P

335651-51-9P 335651-53-1P 335651-55-3P

335651-56-4P 335651-57-5P 335651-58-6P

335651-59-7P 335651-60-0P 335651-61-1P

335651-62-2P 335651-63-3P 335651-64-4P

335651-65-5P 335651-66-6P 335651-67-7P

335651-69-9P 335651-77-9P 335651-88-2P

335651-89-3P 335651-93-9P 335651-94-0P

335651-95-1P 335651-96-2P 335651-97-3P

335651-98-4P 335651-99-5P 335652-00-1P

335652-06-7P 335652-11-4P 335652-12-5P

335652-13-6P 335652-14-7P 335652-16-9P

335652-18-1P 335652-22-7P 335652-24-9P

335652-26-1P 335652-30-7P 335652-32-9P

335652-36-3P 335652-38-6P 335652-40-9P

335652-41-0P 335652-44-3P 335652-46-5P

335652-62-5P 335652-63-6P 335652-64-7P


335652-65-8P 335652-66-9P 335652-67-0P

335652-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335651-19-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-methylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-20-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-methylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-24-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-30-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335651-49-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methylphenyl)-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 335651-50-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[(1-(phenylmethyl)-4-piperidinylamino)- (9CI) (CA INDEX NAME)]




RN 335651-51-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-53-1 CAPLUS
CN 4-Piperidinamine, 1-(methylsulfonyl)-N-[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-55-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[1-[(2R)-2,3-dihydroxypropyl]-4-piperidinylamino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-56-4 CAPLUS
CN 1-Piperidinopropanenitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-57-5 CAPLUS
CN 1-Piperidinacetonitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-58-6 CAPLUS
CN 1-Piperidineacetonitrile, 4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-59-7 CAPLUS
CN 1-Piperidineacetamide, 4-[(2-amino-2-oxoethyl)[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-60-0 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-61-1 CAPLUS
CN 1-Piperidinopropanoic acid, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 335651-62-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-(2,2,2-trifluoroethyl)-4-piperidinyl)methyl]amino)- (9CI) (CA INDEX NAME)




RN 335651-63-3 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 335651-64-4 CAPLUS

CN 1-Piperidineacetamide, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 335651-65-5 CAPLUS

CN 1-Piperidinesacetic acid, 4-[[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 335651-66-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[methyl(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-67-7 CAPLUS

CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335651-69-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 335651-77-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-88-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-ethoxy-1-(ethoxymethyl)ethyl]-3,4-dihydro-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335651-89-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1S)-2-hydroxy-1-methylethyl]amino]-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-93-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]-1-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-94-0 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-95-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-96-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]-1-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-97-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-98-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[3-(dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-99-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-00-1 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydro-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335652-06-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-11-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-methoxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335652-12-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-(2-methoxyethoxy)cyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-13-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-(acetyloy)cyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-14-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(trans-4-(2-propenyl)cyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-16-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(hydroxymethyl)cyclohexyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-18-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-(2,3-dihydroxypropoxy)cyclohexyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335652-22-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(4-oxocyclohexyl)amino]- (9CI) (CA INDEX NAME)




RN 335652-24-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335652-26-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(trans-4-hydroxycyclohexyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-30-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxymethyl)cyclohexylamino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335652-32-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-36-3 CAPLUS
 CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-44-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-46-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2,3-dihydroxy-1-methylpropylamino]-3,4-dihydro-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-47-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335652-39-6 CAPLUS
 CN Methanesulfonamide, N-[(trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-40-9 CAPLUS
 CN Sulfamide, N'-(trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-41-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-48-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(1R,2R)-2,3-dihydroxy-1-methylpropylamino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-50-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2R)-2,3-dihydroxy-1-methylpropylamino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 335652-55-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-acetyl oxy)cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 335652-56-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclopentyl]amino- (9CI) (CA INDEX NAME)



RN 335652-58-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclohexyl]amino- (9CI) (CA INDEX NAME)




RN 335652-59-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxycyclohexyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 335652-60-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(cis-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-61-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-




RN 335652-62-5 CAPLUS
CN Carboxic acid, trans-4-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-63-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-[(aminocarbonyl)oxy]cyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-64-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-[(methylamino)carbonyl]oxy)cyclohexyl]amino- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-65-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-oxocyclohexyl)amino]- (9CI) (CA INDEX NAME)




RN 335652-66-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-ylamino)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 335652-67-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-68-1 CAPLUS
CN Sulfamide, N-[trans-4-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 335651-10-8P 335651-21-3P 335651-22-4P
335651-23-5P 335651-25-7P 335651-26-8P
335651-27-9P 335651-28-0P 335651-29-1P
335651-31-5P 335651-32-6P 335651-33-7P
335651-34-8P 335651-36-0P 335651-37-1P
335651-38-2P 335651-39-3P 335651-40-6P
335651-41-7P 335651-42-8P 335651-43-9P
335651-44-0P 335651-45-1P 335651-46-2P
335651-47-3P 335651-48-4P 335651-52-0P
335651-54-2P 335651-68-9P 335651-70-5P
335651-71-3P 335651-72-4P 335651-73-5P
335651-74-6P 335651-75-7P 335651-76-8P
335651-78-0P 335651-79-1P 335651-80-4P
335651-81-5P 335651-82-6P 335651-83-7P
335651-84-8P 335651-85-9P 335651-86-0P
335651-87-1P 335651-90-6P 335651-91-7P
335651-92-8P 335652-02-3P 335652-04-5P
335652-08-9P 335652-10-3P 335652-20-5P
335652-20-3P 335652-34-1P 335652-37-4P
335652-38-5P 335652-42-1P 335652-43-2P
335652-45-4P 335652-49-8P 335652-51-2P
335652-52-3P 335652-53-4P 335652-54-5P
335652-57-6P 335652-69-2P 335652-70-5P
335652-71-6P 335652-72-7P 335652-73-8P
335652-74-9P 335652-75-0P 335652-76-1P
335652-77-2P 335652-78-3P 335652-79-4P
335652-80-7P 335652-81-8P 335652-82-9P
335652-83-0P 335652-84-1P 335652-85-2P
335652-86-3P 335652-87-4P 335652-88-5P
335652-90-9P 335652-91-0P 335652-92-1P
335652-93-2P 335652-94-3P 335652-95-4P
335652-96-5P 335652-97-6P 335652-98-7P
335652-99-8P 335653-00-4P 335653-01-5P
335653-02-6P 335653-03-7P 335653-04-8P
335653-05-9P 335653-06-0P 335653-07-1P
335653-08-2P 335653-09-3P 335653-10-6P
335653-11-7P 335653-12-8P 335653-13-9P
335653-16-2P 335653-17-3P 335653-18-4P
335653-19-5P 335653-20-6P 335653-21-9P
335653-22-0P 335653-23-1P 335653-24-2P
335653-25-3P 335653-26-4P 335653-27-5P
335653-28-6P 335653-29-7P 335653-30-0P
335653-31-1P 335653-32-2P 335653-33-3P
335653-34-4P 335653-35-5P 335653-36-6P
335653-37-7P 335653-38-8P


RL (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 prepn. of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase
 RN 335651-18-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxyethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-21-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-22-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-23-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxypropyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335651-28-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-29-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-31-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-32-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-25-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-26-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxybutyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-27-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxybutyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-33-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)butyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-34-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-36-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-37-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-38-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-39-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclopentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-40-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-41-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-42-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(1-piperidinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-43-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(1-piperidinyl)propyl)amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-44-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(4-morpholinyl)ethyl)amino]- (9CI) (CA INDEX NAME)



RN 335651-45-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(4-morpholinyl)propyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-46-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-47-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(2-oxo-1-imidazolidinyl)ethyl)amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-48-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]- (9CI) (CA INDEX NAME)



RN 335651-52-0 CAPLUS
 CN 1-Piperideineacetamide, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-54-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1-(2-hydroxyethyl)-4-piperidinyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-68-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (2,2,2-trifluoroethyl)-4-piperidinylamino]- (9CI) (CA INDEX NAME)



RN 335651-70-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{(3-amino-2,2-dimethylpropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-71-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{(3-amino-2,2-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-72-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2-dimethylaminoethyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxymethylpropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-78-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 335651-79-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-80-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335651-73-5 CAPLUS
 CN Acetamide, N-[2-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 335651-74-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-75-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-76-8 CAPLUS


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335651-81-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335651-82-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-83-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1-hydroxymethyl)-2-methylpropyl]amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-84-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 335651-85-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-86-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-87-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-90-6 CAPLUS


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335651-91-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1S,2S)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-92-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-02-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S,2S)-2-hydroxymethyl]propylamino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.




RN 335652-04-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-08-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-10-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-methoxycyclohexyl)methylamino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Relative stereochemistry.




RN 335652-20-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-ylamino)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335652-28-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-34-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-37-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetonitrile, 3-(2-chlorophenyl)-3,4-dihydro-7-[trans-4-hydroxycyclohexyl]amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-38-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-42-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 335652-43-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 335652-45-4 CAPLUS
CN Butanoic acid, 3-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 335652-49-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




RN 335652-51-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-phenylethyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-52-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-53-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2-ethoxy-1-ethoxymethyl)ethyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 335652-54-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-

Absolute stereochemistry.




RN 335652-57-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-formyloxy)cyclohexyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-69-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-70-5 CAPLUS
CN Methanesulfonamide, N-[trans-4-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335652-71-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[2-hydroxy-1-(dimethylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-72-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 335652-73-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[2-

(Continued)
hydroxy-1-methylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-74-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[2-hydroxypropyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-75-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydro-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-76-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxymethyl)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-77-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-78-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(4-oxocyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335652-79-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxylimino)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-80-7 CAPLUS
CN 1,3-Diazaspiro[4.5]decano-2,4-dione, 8-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-2-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-81-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(trans-4-(2-propenyl)oxy)cyclohexyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-82-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[{(trans-4-methoxycyclohexyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-83-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[{(trans-4-(2-methoxyethoxy)cyclohexyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-84-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{trans-4-(acetoxy)cyclohexyl}amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-85-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[{(2S)-2,3-dihydropropoxypyropoxy)cyclohexyl}amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335652-86-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

RN 335652-87-4 CAPLUS
 CN Methanesulfonamide, N-[{trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-1-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl}-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335652-88-5 CAPLUS
 CN Sulfamide, N'-[{trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-1-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl}-, N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 335652-90-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[{(trans-4-hydroxycyclohexyl)amino]-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-91-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-92-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[(1-(phenylmethyl)-4-piperidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




● HCl

RN 335652-96-5 CAPLUS
CN 1-Piperidinepropanoic acid, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-97-6 CAPLUS
CN 1-Piperideineacetamide, 4-[(2-amino-2-oxoethyl)[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-93-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1-[(2R)-2,3-dihydroxypropyl]-4-piperidinyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 335652-94-3 CAPLUS
CN 1-Piperideinepropanenitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-95-4 CAPLUS
CN 1-Piperideineacetonitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Piperidinamine, 1-(methylsulfonyl)-N-[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-99-8 CAPLUS
CN 1-Piperideineacetonitrile, 4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-00-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2-(1-pyrrolidinyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-01-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-02-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-03-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-04-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-ethoxy-1-(ethoxymethyl)ethyl]-3,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-05-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-06-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335653-07-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-08-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-09-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclopentyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



● HCl

RN 335653-10-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1-hydroxymethyl)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-11-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(methyl(1-methyl-4-piperidinyl)amino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-12-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(cis-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



● HCl

RN 335653-13-9 CAPLUS


CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-16-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxycyclohexyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-17-3 CAPLUS

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)

● 2 HCl

RN 335653-18-4 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335653-19-5 CAPLUS

CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335653-20-8 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 335653-21-9 CAPLUS

CN 1-Piperidineacetic acid, 4-[[6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-22-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(methylthio)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-23-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[3-(dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-24-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-25-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335653-26-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxymethyl)cyclohexyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-27-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-28-6 CAPLUS

CN Sulfamide, N'-(trans-4-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 335653-29-7 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-ylamino)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335653-30-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-oxocyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335653-31-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 335653-32-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Sulfamide, N⁻-(trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[(2-trimethylsilyl)ethoxy]methyl]pyrimido[4,5-d]pyrimidin-2-yl]amino)cyclohexyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-75-3 CAPLUS
 CN Butanoic acid, 3-[(6-(2-chlorophenyl)-1,5,6,7-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 335653-76-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-77-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335653-78-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetonitrile, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335653-79-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-80-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-1-[2-(phenylmethyl)-2-oxo-


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [tris(1-methylethyl)silyl]oxy]ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335653-84-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-[2-(tris(1-methylethyl)silyl)ethoxy]methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335653-85-5 CAPLUS
 CN Methanesulfonamide, N-[trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[(2-trimethylsilyl)ethoxy]methyl)pyrimido[4,5-d]pyrimidin-2-yl]amino)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001300720 CAPLUS

DOCUMENT NUMBER: 134:311223

TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p38 protein kinase

INVENTOR(S): Dunn, James Patrick; Goldstein, David Michael; Harris, William; Smith, Ian Edward David; Welch, Teresa Rosanne

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|------------|
| WO 2001029041 | A1 | 20010426 | WO 2000-EP10077 | 20001013 |
| W: AE, AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2388140 | AA | 20010426 | CA 2000-2388140 | 20001013 |
| BR 2000014973 | A | 20020716 | BR 2000-14973 | 20001013 |
| TR 200201058 | T2 | 20020722 | TR 2002-200201058 | 20001013 |
| EP 1226144 | A1 | 20020731 | EP 2000-972755 | 20001013 |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2003512377 | T2 | 20030402 | JP 2001-531839 | 20001013 |
| AU 776695 | B2 | 20040916 | AU 2001-11375 | 20001013 |
| US 6642241 | B1 | 20031104 | US 2000-693364 | 20001020 |
| ZA 2002002603 | A | 20030703 | ZA 2002-2603 | 20020403 |
| NO 2002001783 | A | 20020416 | NO 2002-1783 | 20020416 |
| PRIORITY APPLN. INFO.: | | | US 1999-160804P | P 19991021 |
| | | | US 2000-213718P | P 20000622 |
| | | | WO 2000-EP10077 | W 20001013 |

OTHER SOURCE(S): MARPAT 134:311223
 GI



AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl,


L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclyl, etc.; n = 0-3), were prep'd. for pharmaceutical use as inhibitors of p38 protein kinase for the treatment of conditions such as arthritis, Crohn's disease, obstructive pulmonary disease, or irritable bowel syndrome.. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NHCHMe₂; R3 = CH₂CO₂H) was prep'd. via a substitution reaction of H₂NCHMe₂ with sulfone II (R = SO₂CH₂Ph, R3 = CH₂CO₂Et) when combined and heated to 90-100° for 1 h. The prep'd. dihydropyrimido[4,5-d]pyrimidinone derivs. showed p38 50% inhibitory activity at concns. < 10 μM.

IT 335318-15-5P 335318-19-9P 335318-22-4P
 335318-39-3P 335318-40-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335318-15-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-hydroxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 335318-19-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 335318-22-4 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (prep'n. of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335318-09-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 335318-10-0 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335318-11-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335318-12-2 CAPLUS

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 335318-39-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 335318-40-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




IT 335318-09-7P 335318-10-0P 335318-11-1P

335318-12-2P 335318-16-6P 335318-17-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335318-16-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2R)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335318-17-7 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 335318-18-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 335318-27-9 335318-33-7P 335318-38-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)
 RN 335318-27-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-[(tris(1-methylethyl)silyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 335318-33-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 335318-38-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:291041 CAPLUS
 DOCUMENT NUMBER: 132:308352
 TITLE: Preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors
 INVENTOR(S): Harris, William; Hill, Christopher Huw; Smith, Ian Edward David
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|----------|
| WO 2000024744 | A1 | 20000504 | WO 1999-EP7675 | 19991013 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SI, TR, TM, TR, TT, UA, UG, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| GW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2347474 | AA | 20000504 | CA 1999-2347474 | 19991013 |
| BR 9914677 | A | 20010717 | BR 1999-14677 | 19991013 |
| EP 1123295 | A1 | 20010816 | EP 1999-953796 | 19991013 |
| EP 1123295 | B1 | 20040929 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| TR 200101102 | T2 | 20020121 | TR 2001-200101102 | 19991013 |
| JP 2002528455 | T2 | 20020903 | JP 2000-578314 | 19991013 |
| JP 3593035 | B2 | 20041124 | | |
| NZ 510760 | A | 20030829 | NZ 1999-510760 | 19991013 |
| AU 769989 | B2 | 20040212 | AU 2000-10363 | 19991013 |
| AT 277931 | E | 20041015 | AT 1999-953796 | 19991013 |
| US 6150373 | A | 20001121 | US 1999-422451 | 19991021 |
| ZA 2001002652 | A | 20020930 | ZA 2001-2652 | 20010330 |
| HR 200100274 | A1 | 20020630 | HR 2001-274 | 20010412 |
| NO 2001001929 | A | 20010419 | NO 2001-1929 | 20010419 |
| HK 1041483 | A1 | 20041224 | HK 2002-103084 | 20020424 |
| PRIORITY APPLN. INFO.: GB 1998-23277 A 19981023 | | | | |
| GB 1999-20044 A 19990824 | | | | |
| WO 1999-EP7675 W 19991013 | | | | |

OTHER SOURCE(S): MARPAT 132:308352
 GI




AB Title compds. [I]: R1 = NH2, alkylamino, (hetero)aryl(alkyl)amino; R2 =

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 alkyl (hetero)aryl(alkyl); R3 = H, alkyl, (hetero)aryl(alkyl), cycloalkenyl were prep'd. Thus, Et 4-chloro-2-methylthiopyrimidine-5-carboxylate was aminated by MeNH2 and the product converted to the aldehyde which was condensed with 2,6-Cl2C6H3NH2 (R1 = 2-methylthiopyrimidine-5,4-diyl). The latter was cyclcondensed with COCl2 and the product oxidized to give I (R2 = 2,6-Cl2C6H3NH2, R3 = Me) (II; R1 = SO2Me) which was aminated by 4-(H2N)C6H4OCH2CH2NH2 (prepn. given) to give II (R1 = 4-(Et2N)C6H2CH2O)C6H4NH). Data for biol. activity of I were given.


IT 266312-86-1P 266312-87-2P 266312-88-3P
 266312-93-0P 266312-94-1P 266312-95-2P
 266312-97-4P 266312-98-5P 266312-99-6P
 266313-00-2P 266313-01-3P 266313-02-4P
 266313-03-5P 266313-04-6P 266313-05-7P
 266313-06-8P 266313-07-9P 266313-08-0P
 266313-09-1P 266313-10-4P 266313-11-5P
 266313-12-6P 266313-13-7P 266313-14-8P
 266313-15-9P 266313-16-0P 266313-17-1P
 266313-18-2P 266313-19-3P 266313-20-6P
 266313-21-7P 266313-22-8P 266313-23-9P
 266313-24-0P 266313-25-1P 266313-27-3P
 266313-29-5P 266313-30-0P 266313-31-9P
 266313-32-3P 266313-33-1P 266313-34-2P
 266313-35-3P 266313-36-4P 266313-37-5P
 266313-38-6P 266313-39-7P 266313-40-0P
 266313-41-1P 266313-42-2P 266313-43-3P
 266313-44-4P 266313-45-5P 266313-46-6P
 266313-47-7P 266313-48-8P 266313-49-9P
 266313-50-2P 266313-51-3P 266313-52-4P
 266313-53-5P 266313-54-6P 266313-55-7P
 266313-56-8P 266313-57-9P 266313-58-0P
 266313-59-1P 266313-60-4P 266313-61-5P
 266313-62-6P 266313-63-7P 266313-64-8P
 266313-65-9P 266313-66-0P 266313-67-1P
 266313-68-2P 266313-69-3P 266313-70-6P
 266313-71-7P 266313-73-9P 266313-74-0P
 266313-75-1P 266313-76-2P 266313-77-3P
 266313-78-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses); (preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)

INVENTOR(S):
 RN 266312-86-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266312-87-2 CAPLUS


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266312-88-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266312-93-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266312-94-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CMF C2 H F3 O2




RN 266312-98-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 266312-99-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-00-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-01-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266312-95-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 266312-97-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-(3-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 266312-96-3
 CMF C30 H31 Cl2 N7 O2




CM 2

CRN 76-05-1


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-02-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(dimethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-03-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-(2-hydroxyethyl)phenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-04-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 266313-05-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-(2,4-dimethoxyphenyl)methyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-06-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-07-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(cyclohexylamino)-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-08-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-13-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2-(4-aminophenyl)ethylamino)-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-14-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)methylamino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-15-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)methylamino]-3-(2,6-dimethylphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-16-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)methylamino]-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 266313-09-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 266313-10-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(cyclohexylmethyl)amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-11-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-naphthalenylamino)-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-12-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(aminomethyl)phenyl]methylamino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-17-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-3,4-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 266313-18-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(2-(diethylamino)ethoxy)phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 266313-19-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-20-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)methylamino]-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-21-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-22-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(2,6-difluorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-23-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-24-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-(3-(2,6-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266313-25-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(3-(2-aminoethyl)phenyl)-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-27-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-29-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(2-cyclohexen-1-yl)-3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-30-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-31-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,5-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)





RN 266313-32-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-bromophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-33-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-34-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-hydroxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 266313-36-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 266313-37-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-38-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-dimethylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-39-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-[2-chloro-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 4-(trifluoromethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-40-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-41-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-chloro-6-methylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-42-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,5-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-43-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[{4-[2-(diethylamino)ethoxy]phenyl}amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-44-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxy-1,1-dimethylethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-45-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-1,1-dimethylethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-46-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[{4-(methoxyphenyl)amino}- (9CI) (CA INDEX NAME)



RN 266313-47-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[{4-hydroxyphenyl}amino]- (9CI) (CA INDEX NAME)




RN 266313-48-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



RN 266313-49-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-50-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-51-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266313-52-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-(1-naphthalenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-53-5 CAPLUS
 CN Benzoic acid, 3-[(3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 266313-54-6 CAPLUS
 CN Benzoic acid, 3-[(3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl)- (9CI) (CA INDEX NAME)



RN 266313-55-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-ethoxyphenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-56-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-57-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-methylaminoethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266313-58-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-(2-dimethylaminoethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-59-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-60-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-61-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-(2-(methylamino)ethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-62-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-(2-(dimethylamino)ethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-63-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-(cyclohexylmethyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-67-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro-1-(3-(2-hydroxyethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 266313-68-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-69-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-1-[3-(2-(dimethylamino)ethyl)phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-61-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-65-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-66-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro-1-methyl-3-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 266313-67-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro-1-(3-(2-hydroxyethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 266313-68-2 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-69-3 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-1-[3-(2-(dimethylamino)ethyl)phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-70-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-(2-(diethylamino)ethoxy)phenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-71-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-2-methylpropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-73-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(1-aminomethyl)-1-ethylpropyl]phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 266313-72-8
CMF C30 H30 Cl2 N6 O




CM 2
CRN 76-05-1
CIP C2 H F3 O2




RN 266313-74-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(3-aminopropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-75-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-(2-diethylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-76-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-(4-morpholinyl)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-77-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-(2-(1-piperazinyl)ethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-78-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[{(2-furanyl)methyl}amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




IT 266314-05-0P 266314-38-9P 266314-39-0P
266314-40-3P 266314-45-8P 266314-46-9P
266314-47-0P 266314-48-1P 266314-49-2P
266314-51-6P 266314-62-9P 266314-63-0P
266314-71-0P 266314-78-7P 266314-79-8P
266314-83-4P 266314-84-5P 266314-86-7P
266314-91-4P 266314-92-5P 266314-93-6P
266315-34-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)
RN 266314-05-0 CAPLUS
CN Benzenesacetic acid, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 266314-38-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-39-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-40-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-45-8 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-1-[3-[(1,1-dimethylethyl)diphenylsilyloxyethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-46-9 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-47-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-(3-(2-chloro-6-methylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimidin-1(2H)-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 266314-62-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[{3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl}methyl]- (9CI) (CA INDEX NAME)




RN 266314-63-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266314-71-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[{4-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl}methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 266314-48-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-(3-(2,5-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-49-2 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-{3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1,1-dimethylethyl}phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-51-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 266314-78-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-{3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl}phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-79-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-{3-[2-[(methylsulfonyl)oxy]ethyl}phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-83-4 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)




RN 266314-84-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-86-7 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)




RN 266314-91-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-[(1,1-dimethylethyl)dimethylsilyloxy]ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266314-92-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-[(2-diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-[3-[(methylsulfonyl)oxy]ethyl]phenyl] - (9CI) (CA INDEX NAME)



RN 266314-93-6 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]ethyl] - (9CI) (CA INDEX NAME)



RN 266315-34-8 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[3-(3-(2,6-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]propyl] - (9CI)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:764041 CAPLUS
 DOCUMENT NUMBER: 132:22971
 TITLE: Preparation of oxypyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors
 INVENTOR(S): Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conradi; Shwalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer, Susanne A.
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: PCT Int. Appl., 133 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|-------------|
| WO 9961444 | A2 | 19991202 | WO 1999-US10187 | 19990510 |
| WO 9961444 | A3 | 20000203 | | |
| W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CL, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ,UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2329703 | AA | 19991202 | CA 1999-2329703 | 19990510 |
| AU 9940734 | A1 | 19991213 | AU 1999-40734 | 19990510 |
| AU 763839 | B2 | 20030731 | | |
| BR 9911590 | A | 20010213 | BR 1999-11590 | 19990510 |
| EP 1080092 | A2 | 20010307 | EP 1999-924165 | 19990510 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| TR 200003429 | T2 | 20010723 | TR 2000-200003429 | 19990510 |
| JR 2002516327 | T2 | 20020604 | JR 2000-550849 | 19990510 |
| EE 200000706 | A | 20020617 | EE 2000-706 | 19990510 |
| NZ 508268 | A | 20040227 | NZ 1999-508268 | 19990510 |
| ZA 2000006536 | A | 20020211 | ZA 2000-6536 | 20001110 |
| BG 104960 | A | 20010131 | BG 2000-104960 | 20001117 |
| HR 2000007799 | A1 | 20010630 | HR 2000-799 | 20001120 |
| NO 2000005928 | A | 20001123 | NO 2000-5928 | 20001123 |
| HK 1039483 | A1 | 20040618 | HK 2001-107828 | 20011108 |
| US 2004044012 | A1 | 20040304 | US 2003-638848 | 20030811 |
| | | | US 1998-86708P | P 19980526 |
| | | | US 1999-126158P | P 19990325 |
| | | | WO 1999-US10187 | W 19990510 |
| | | | US 2000-623737 | A3 20000907 |

PRIORITY APPLN. INFO.: MARPAT 132:22971
 OTHER SOURCE(S): GI

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. [I; G = NR2 or CHR2; R = NH(R1) or SOO-2R1; R1,R2 = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R3 = groups cited for R1, OH, alkoxycarbonyl, etc.; R4 = bond; R8,R9 = H, halo, NH2, alkoxycarbonyl, etc.; X = O, S, (alkyl)amino, etc.; Z = N or CH2] were prepared as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (preparation given)

was cyclocondensed with 1,1'-carbonyldiimidazole and the oxidized product aminated by 4-(MeO)C6H4NH2 to give I [G = cyclopentylimino, R = 4-(MeO)C6H4NH2, R3 = R4 = R8 = R9 = H, X = O]. Data for biol. activity of I were given.

IT 251370-13-2P 251370-14-6P 251370-15-7P

251370-16-1P 251370-17-9P 251370-18-0P

251370-19-1P 251370-20-4P 251370-21-5P

251370-22-6P 251370-23-7P 251370-24-8P

251370-25-9P 251370-26-0P 251370-27-1P

251370-28-2P 251370-29-3P 251370-30-6P

251370-31-7P 251370-32-8P 251370-33-9P

251370-34-0P 251370-35-1P 251370-36-2P

251370-37-3P 251370-38-4P 251370-39-5P

251370-40-6P 251370-66-8P 251370-67-9P

251370-68-9P 251371-07-0P 251371-08-1P

251371-09-1P 251371-10-5P 251371-11-6P

251371-12-7P 251371-13-8P 251371-14-9P

251371-15-0P 251371-16-1P 251371-17-2P

251371-18-3P 251371-19-4P 251371-20-7P

251371-21-8P 251371-22-9P 251371-63-2P

251371-84-3P 251371-85-4P 251371-86-5P

251371-87-6P 251371-88-7P 251371-89-8P

251371-90-1P 251371-91-2P 251371-92-3P

251371-93-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines)

as inhibitors of cellular proliferation)


RN 251370-13-2 CAPLUS

CN Piperazine, 1-(aminoacetyl)-4-[4-[(6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251370-14-6 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[4-[(6-(2-chloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-15-7 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[4-[(6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-16-8 CAPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[4-[(6-(3,5-dimethoxy-2-methylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-17-9 CAPLUS

CN Piperazine, 1-(aminoacetyl)-4-[4-[(6-(3,5-dimethoxy-2,6-dimethylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-18-0 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[4-(2-diethylamino)ethoxy]phenyl]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-19-1 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[(2-diethylamino)ethoxy]phenyl]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN


(Continued)



RN 251370-20-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-
[4-(2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA
INDEX NAME)




RN 251370-21-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-[3-(5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-22-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on ST


(Continued)




RN 251370-23-7 CAPLUS
CN Pyrimidin-4-(5-d₄-pyrimidin-2(1H)-one, 7-[(4-(diethylamino)butyl]amino)-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-24-8 CAPIUS
CN Pyrimidin-4-(5-d-pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[(4-(diethylamino)butyl)amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-25-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-((4-[dimethylamino]butyl)amino)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251370-26-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{4-(diethylamino)butyl}amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-27-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-28-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-29-3 CAPLUS
CN Pyrimidin-4,5-dipyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-*N*-(4-methylpiperazin-1-yl)-¹⁸CrCl₃ (CPD INDEX NAME)


L4 ANSWER 14 OF 16 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-30-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-31-7 CAPLUS
CN Pyrimidin-4-(5-dimethylaminopyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro-7-*alpha*-methyl-, (9CI) (CA INDEX NAME)




RN 251370-32-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro-2-(4-micropiperazine-1-oxyl)- (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 251370-33-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-34-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[(4-diethylamino)butyl]amino-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-35-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-36-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-66-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[(4-diethylamino)butyl]amino-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)




RN 251370-67-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)




RN 251370-68-0 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251370-37-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-38-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-39-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-40-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 251371-07-0 CAPLUS
 CN Benzoic acid, 3-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-08-1 CAPLUS
 CN Benzamide, 3-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-09-2 CAPLUS
 CN Benzamide, 3-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-10-5 CAPLUS
 CN Benzoic acid, 3-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-11-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-(2-ethylamino)ethoxy)phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-12-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-(2-ethylamino)ethoxy)phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-13-8 CAPLUS
CN Benzamide, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-14-9 CAPLUS
CN Benzamide, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-15-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(3-(hydroxymethyl)phenyl)amino]- (9CI) (CA INDEX NAME)




RN 251371-16-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-(morpholinyl)phenyl)amino]- (9CI) (CA INDEX NAME)




RN 251371-17-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(4-(4-morpholinyl)phenyl)amino]- (9CI) (CA INDEX NAME)




RN 251371-18-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(3-(hydroxymethyl)phenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-19-4 CAPLUS
CN Benzenecarboxylic acid, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-20-7 CAPLUS
CN Benzenecarboxylic acid, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)



RN 251371-21-8 CAPLUS
CN Benzaldehyde, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-22-9 CAPLUS
CN Benzaldehyde, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-83-2 CAPLUS


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[(4-(diethylamino)butyl)amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251371-84-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-[(4-pyridinylmethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-85-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-86-5 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-87-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251371-88-7 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251371-89-8 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[2-[(4-pyridinylmethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-90-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-91-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251371-92-3 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)





RN 251371-93-4 CAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



IT 251372-03-PP 251372-05-IP
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as


as
 inhibitors of cellular proliferation)
 RN 251372-03-9 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-7-[(4-(4-methyl-1-piperazinyl)phenyl)amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (diethylaminoethoxyphenyl)amino]-3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 251372-05-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-(2-

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:209801 CAPLUS
 DOCUMENT NUMBER: 130:338080
 TITLE: A solid phase approach to substituted pyrimidines and their conversion into condensed heterocycles for potential use in combinatorial chemistry
 AUTHOR(S): Srivastava, Sanjay K.; Haq, W.; Chauhan, P. M. S.
 CORPORATE SOURCE: Divisions of Medicinal Chemistry and Biopolymers, Central Drug Research Institute, Lucknow, 226001, India
 SOURCE: Combinatorial Chemistry and High Throughput Screening (1999), 2(1), 33-37
 CODEN: CCHSFU; ISSN: 1386-2073
 PUBLISHER: Bentham Science Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A novel general synthesis of substituted pyrimidines has been carried out on a solid support. The C-atoms carrying the cyano, amino, carboxamido, as well as the anchoring site have been exploited to generate libraries of compds. Synthesis of 2,5,6-trisubstituted pyrimidines was carried out by nucleophilic displacement of the anchor by various amines. Further investigations were directed toward the solid phase synthesis of pyrimido[4,5-d]pyrimidines.
 IT 224575-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of pyrimidines and their conversion into condensed heterocycles)
 RN 224575-96-6 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-(cyclohexylamino)-3-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1991:408712 CAPLUS
 DOCUMENT NUMBER: 115:8712
 TITLE: Synthesis of 2,4-diamino-5-acetyl(ethoxycarbonyl)pyrimidines from β -dicarbonyl compounds and dicyandiamide and their application for the construction of pyrimido[4,5-d]pyrimidine system
 AUTHOR(S): Dorokhov, V. A.; Gordeev, M. F.; Komkov, A. V.; Bogdanov, V. S.
 CORPORATE SOURCE: Inst. Org. Khim. im. Zelinskogo, Moscow, USSR
 SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1991), (1), 159-64
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 115:8712
 GI



AB The reaction of MeCOCH₂COMe or RCOCH₂COR₁ (R = Me, Ph; R₁ = Me, OEt) with H₂N(NH₂):NCO in the presence of Ni(OAc)₂ gives pyrimidines I. Regiospecific annelation of I. (after protection of the 2-NH₂ group) with PhNCO or (MeO)CH₂Me gives pyrimidopyrimidines, e.g., II, III, IV.
 IT 134221-31-1P 134221-32-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 134221-31-1 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 134221-32-2 CAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-3,5-diphenyl- (9CI) (CA INDEX NAME)

